We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program
News

Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program

Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program
News

Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that the Flemish Agency for Innovation through Science and Technology (IWT) has awarded a €1.6 million grant to support the development of new antiviral therapies against hepatitis B, in a collaboration project with Prof. Johan Neyts of the Rega Institute of the University of Leuven and Prof. Stephan Urban of the University Hospital in Heidelberg.

The goal of the project is to identify novel compounds and targets with the potential to cure chronic hepatitis B infection, allowing patients to come off current life-long therapy.

Galapagos will use its proprietary target and drug discovery platform to identify novel modes of action and screen for candidate drugs. The Rega and Heidelberg sites will contribute to the development of assays, perform analysis of the mechanism of action of drug candidates, and bring in expertise of the virus and its life cycle to accelerate the progression of drug development.

"Chronic hepatitis B is a disease area with significant unmet medical need, and where Galapagos and its academic partners can bring unique expertise to bear on finding new therapies," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.

"It would be an enormous advance if patients could be cured of their chronic HBV infection" said Prof. Johan Neyts, virologist at the University of Leuven.

Advertisement